Mainstream Demand
GLP-1 adoption brought peptide therapies into broad public awareness and expanded demand across the category.
Confidential Investor Overview · May 2026
Sequence One Peptide Manufacturing Venture
A US-based peptide manufacturing operation positioned for scalable, compliant production.
$500K+
Invested to date
$250K+
Initial monthly commitments
$500K-$1M
SAFE investment range
The Opportunity
Rising demand creates an opening for domestic peptide manufacturing.
Peptide demand has expanded rapidly following mainstream GLP-1 adoption. At the same time, regulatory changes and the domestic supply gap create an opportunity for US-based production.
Domestic Supply Gap
The venture is positioned around US-based manufacturing, faster domestic fulfillment, and scalable production capacity.
Regulatory Timing
The market is shifting toward a more structured, legal, and quality-driven domestic manufacturing environment.
Status & Traction
Our facility is secured. Buildout is underway. Demand is already in place.
We have secured our Long Beach facility, begun the FDA-compliant buildout, started acquiring manufacturing equipment, and established early wholesale sales commitments.
Long Beach
Facility secured
$500K+
Invested to date
$250K+
Initial monthly sales commitments
2 months
Expected path to wholesale production
Wholesale-First Model
Wholesale revenue provides the foundation for channel expansion.
The initial focus is domestic manufacturing and wholesale fulfillment. Additional sales channels, R&D, AI modeling, clinical testing, and IP protection create longer-term growth opportunities.
Phase One
Wholesale Production
Fulfill existing wholesale commitments and expand domestic sales relationships.
→
Phase Two
Channel Expansion
Develop additional compliant sales channels, including a consumer-facing website.
→
Phase Three
R&D and IP Development
Explore AI modeling, clinical trials, new peptide options, and IP protection.
Operating Economics
Scalable, high-margin production.
The operating model is built around 2,000 vials per shift with a stated sell price of $24-$29 per vial and a stated production cost of $14 per vial.
2,000
Vials per shift
$24-$29
Sell price per vial
$14
Cost per vial
$20K-$30K
Profit per shift
At two shifts per day, the model supports $40K-$60K in daily profit and $14.6M-$21.9M in annual net profit at full-scale operation. Detailed operating assumptions are included in the appendix.
Investor Materials
Download the deck and supporting appendix.
The investor deck presents the core business case. The appendix provides additional context, detailed unit economics, use of funds, diligence categories, risks, and disclosure language.
PDF · Core Presentation
Investor Deck
A focused presentation covering the opportunity, traction, operating model, economics, investment case, and call to action.
Download deckPDF · Supporting Materials
Appendix
Supporting detail covering the category, regulatory context, market trajectory, manufacturing process, unit economics, use of funds, diligence, risks, and disclaimer.
Download appendixPDF · Combined File
Full Presentation
The investor deck and supporting appendix combined into a single confidential PDF for convenient review.
Download full PDFDisclosure
Investor materials.
These materials are intended solely for informational purposes and confidential review. Review the full disclaimer before downloading or distributing the presentation.
Read full disclaimer
Disclaimer: This presentation is confidential and has been prepared by Company solely for informational purposes. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction. The securities offered by the Company have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and are being offered in reliance upon exemptions from such registration. This includes exemptions from securities registration since it is a seed capital exemption under Rule 504, is not a general solicitation and a safe harbor offering pursuant to Rule 506, and is also exempt under California as a limited offer exemption under Cal. Code § 25102(f), a small offering exemption Cal. Code § 25102(h), an employee/consultant compensation plan under Cal. Code § 25102(o), as well as that Purchaser is a qualified or accredited investor.
This presentation contains forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements. Past performance is not indicative of future results. Prospective investors should make their own investigations and evaluations of the Company. By accepting this presentation, the recipient agrees to keep the information contained herein strictly confidential.